Biocon Limited on Friday, November 14, issued a clarification to the stock exchanges under Regulation 30(11), responding to media reports claiming that the company was considering a merger of Biocon Biologics Limited (BBL) with the listed entity, including IPO and share-swap options.
In its statement, Biocon said the speculation traces back to its earlier press release dated May 08, 2025, where the company had announced that its Board had constituted a committee to evaluate a range of strategic restructuring options, including a potential merger of BBL with Biocon. The company reiterated that the committee is still examining all possibilities, taking into account legal, tax and regulatory requirements.
Biocon also confirmed that no material event or information requiring disclosure has arisen at this stage. The company emphasised that it follows the highest governance standards and will make timely disclosures as and when required under SEBI regulations.
The clarification has been uploaded to the company’s website and submitted to both BSE and NSE.
Disclaimer: The information provided is for informational purposes only and should not be considered financial or investment advice. Stock market investments are subject to market risks. Always conduct your own research or consult a financial advisor before making investment decisions. Author or Business Upturn is not liable for any losses arising from the use of this information.
